Loading…
Arvinas, Inc. is projected to rise to $9.44 by 2027, a +18% move from its current price of $8.03. ARVN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $7.89 | $8.03 | $8.18 | +0.01% |
| Aug 3 | $7.83 | $8.03 | $8.24 | +0.01% |
| Aug 4 | $7.79 | $8.03 | $8.28 | +0.02% |
| Aug 5 | $7.75 | $8.03 | $8.32 | +0.02% |
| Aug 6 | $7.72 | $8.03 | $8.36 | +0.03% |
| Aug 7 | $7.69 | $8.03 | $8.39 | +0.04% |
| Aug 8 | $7.66 | $8.03 | $8.42 | +0.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.66 | $8.03 | $8.42 | +0.04% |
| Week 2 | $7.52 | $8.04 | $8.59 | +0.09% |
| Week 3 | $7.41 | $8.04 | $8.73 | +0.13% |
| Week 4 | $7.32 | $8.04 | $8.84 | +0.17% |
| Week 5 | $7.24 | $8.05 | $8.94 | +0.22% |
| Week 6 | $7.17 | $8.05 | $9.04 | +0.26% |
| Week 7 | $7.11 | $8.05 | $9.13 | +0.30% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arvinas, Inc. is a clinical-stage biotechnology company that engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
It is also developing clinical development programs, including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F.
Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Arvinas, Inc. (ARVN) is trading with a current price of $8.30, a market cap of $535.53M, and a rank of 2802. These metrics place it among smaller-cap biotechnology equities with a focused PROTAC therapy platform. The near-term and long-range price outlook is conveyed through a year-by-year forecast that shows varying averages and upside potential.
A major floor 13.1% below — a decisive break under it would weaken the trend.
The nearest floor, 4.5% below — buyers have tended to step in here.
The nearest ceiling, 7.0% above — a clean break opens room to run.
A major ceiling 41.6% above — clearing it would confirm fresh momentum.
Key ARVN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARVN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $8.19 | Sell | $8.16 | Sell |
| MA 10 | $8.17 | Sell | $8.17 | Sell |
| MA 20 | $8.24 | Sell | $8.18 | Sell |
| MA 50 | $8.13 | Sell | $8.47 | Sell |
| MA 100 | $9.42 | Sell | $9.18 | Sell |
| MA 200 | $10.64 | Sell | $10.09 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.68 | Neutral |
| Stoch RSI (14) | 10.89 | Buy |
| CCI (20) | -99.05 | Neutral |
| Williams %R (14) | -93.10 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -3.02 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 6.90 | Buy |
| TRIX (15) | -0.01 | Sell |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 41.84 | Neutral |
| Momentum (10) | 0.02 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 8.21 | Sell |
| ADX (14) | 9.51 | Neutral |
| ATR (14) | 0.13 | Info |
Technically, the sentiment is BULLISH with RSI14 at 50. The stock sits near the 50-day simple moving average of $8.14 and well below the 200-day simple moving average of $10.65. Support is identified at $7.67 and resistance at $8.59.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $6.98 | $8.03 | $10.17 | 0% | Neutral | |
| $7.74 | $9.44 | $12.03 | +18% | Neutral | |
| $7.91 | $9.83 | $12.87 | +22% | Bullish | |
| $8.20 | $10.35 | $13.85 | +29% | Bullish | |
| $8.00 | $10.23 | $13.94 | +27% | Bullish | |
| $8.35 | $10.82 | $14.97 | +35% | Bullish | |
| $10.09 | $13.21 | $18.54 | +65% | Bullish | |
| $10.67 | $14.12 | $20.07 | +76% | Bullish | |
| $11.10 | $14.84 | $21.35 | +85% | Bullish | |
| $11.80 | $15.92 | $23.16 | +98% | Bullish | |
| $16.44 | $23.13 | $35.27 | +188% | Bullish | |
| $24.06 | $36.32 | $59.36 | +352% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $6.98 | $8.03 | $9.82 | +0.00% |
| September 2026 | $6.98 | $8.19 | $9.82 | +1.96% |
| October 2026 | $6.86 | $8.08 | $9.76 | -1.37% |
| November 2026 | $6.96 | $8.23 | $10.01 | +1.95% |
| December 2026 | $7.02 | $8.32 | $10.17 | +1.10% |
Click any year to see its month-by-month ARVN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ARVN to range from $6.98 to $10.17 through 2026. The $8.03 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The ARVN price prediction for 2027 points to an average of $9.44 (low $7.74, high $12.03) — a potential gain of +18% on today's $8.03. A consolidation phase looks the most probable path here.
In 2028, ARVN is projected to trade between $7.91 and $12.87, averaging $9.83 — a potential gain of +22% from today's $8.03. That is up +4% on the projected 2027 average. Momentum favours further upside here.
Arvinas, Inc.'s 2029 outlook centres on $10.35, within a $8.20 to $13.85 range. That is up +5% on the projected 2028 average. That marks a +29% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, ARVN could reach as high as $13.94, with a base case around $10.23 and support toward $8.00 — roughly +27% from $8.03. Momentum favours further upside here.
Expect ARVN to range from $8.35 to $14.97 through 2031. The $10.82 average target implies a +35% move from current prices. That is up +6% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The ARVN price prediction for 2032 points to an average of $13.21 (low $10.09, high $18.54) — a potential gain of +65% on today's $8.03. Momentum favours further upside here.
In 2033, ARVN is projected to trade between $10.67 and $20.07, averaging $14.12 — a potential gain of +76% from today's $8.03. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Arvinas, Inc.'s 2034 outlook centres on $14.84, within a $11.10 to $21.35 range. That is up +5% on the projected 2033 average. That marks a +85% change versus current levels. Momentum favours further upside here.
By 2035, ARVN could reach as high as $23.16, with a base case around $15.92 and support toward $11.80 — roughly +98% from $8.03. Buyers look set to stay in control over this stretch.
Expect ARVN to range from $16.44 to $35.27 through 2040. The $23.13 average target implies a +188% move from current prices. That is up +45% on the projected 2035 average. Momentum favours further upside here.
The ARVN price prediction for 2050 points to an average of $36.32 (low $24.06, high $59.36) — a potential gain of +352% on today's $8.03. Buyers look set to stay in control over this stretch.
Investing $1,000 in ARVN today (≈ 124.533001 ARVN) could be worth
$4,522.87
+$3,522.87 (+352%) by 2050 · US Dollar
Based on the average projected ARVN price of $36.32 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARVNwould be worth at today's price.
$1,000 invested in ARVN on Jul 31, 2025 (≈ 134.408601 ARVN) would be worth
$1,079.3
+$79.3 (+7.9%) today · 1.08× · US Dollar
Based on a ARVN entry price of $7.44 vs. today's $8.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.03 | $1,000 | +0.0% |
| 1 month ago | $8.2 | $979.27 | -2.1% |
| 3 months ago | $10.51 | $764.03 | -23.6% |
| 6 months ago | $13.83 | $580.62 | -41.9% |
| 1 year ago | $7.44 | $1,079.3 | +7.9% |
| All time (5.0y) ago | $97.67 | $82.22 | -91.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARVN forecast.
Our base-case forecast reaches $16.00 around 2040.
Implied market cap at $16.00: $1.03B
The multi-year forecast shows a path of gradual appreciation. For 2026, the min is $6.98, the avg is $8.30, the max is $10.50, with a 0% ROI and Neutral sentiment. In 2027 the avg rises to $9.73 (min $7.98, max $12.40) with 17.2% ROI and Neutral sentiment.
In 2028 the avg is $10.11 (min $8.14, max $13.24) with 21.8% ROI and Bullish sentiment, followed by 2029 avg $10.60 (min $8.40, max $14.18) at 27.7% ROI and Bullish sentiment. The forecast continues to 2030 with avg $10.45 (min $8.17, max $14.24) and 25.9% ROI, and 2031 avg $11.03 (min $8.52, max $15.26) at 32.9% ROI. By 2032 the avg is $13.39 (min $10.22, max $18.79) with 61.4% ROI, and 2033 avg $14.31 (min $10.81, max $20.35) at 72.4% ROI.
The upward trajectory persists through 2034 (avg $15.04, ROI 81.2%), 2035 (avg $16.11, ROI 94%), then accelerates toward 2040 (avg $23.28, ROI 180.5%) and 2050 (avg $36.24, ROI 336.7%). The sentiment in later years is bullish. These figures are estimates and not guarantees, reflecting potential movement under varying conditions.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $10.45 with a min of $8.17 and a max of $14.24, and an estimated ROI of 25.9% with bullish sentiment.
The forecast shows a bullish outlook from 2027 onward, with rising average prices and positive ROI in several years, though 2026 is neutral. These are estimates, not guarantees.
The 2050 forecast maximum is $59.24, which is below $60.
ARVN's current price is $8.30 and its market cap is $535.53M.
For 2027 the average price is $9.73, with a min of $7.98, a max of $12.40, an ROI of 17.2%, and Neutral sentiment.
Arvinas, Inc. Community Discussion
0Share your Arvinas, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.